Orthofix Medical Inc. (OFIX) Form 8-K — Nov 9, 2026
Orthofix reported Q3 2026 net sales of $207.9 million, up 1.1% on a reported basis and 2.3% pro forma constant currency, with a net loss of $6.1 million ($(0.15) per share) and adjusted EBITDA of $26.0 million, up from $24.6 million a year ago. The company cut its full-year 2026 guidance, lowering net sales to $825-$830 million from $845-$855 million and adjusted EBITDA to $86-$88 million from $95-$98 million, citing weak U.S. Spine performance, market softness, supplier delays, and instrument-set constraints.
Key figures
- Revenue
- 207900000
- Guidance
- FY2026 net sales revised to $825M-$830M (from $845M-$855M); non-GAAP adjusted EBITDA revised to $86M-$88M (from $95M-$98M)
- Total Debt
- 221847000
- Revenue Yoy
- 1.1% reported / 2.3% pro forma constant currency
- Total Assets
- 855761000
- Cash Position
- 86900000
- Free cash flow 9m
- -$61.3M vs -$18.1M prior year
- Adjusted ebitda q3
- $26.0M (12.5% of pro forma net sales) vs $24.6M prior year
- Shares outstanding
- 40.7M as of 9/30/2026
- Global spine growth
- +0.9%
- Adjusted net income q3
- $7.5M
- Operating cash flow 9m
- -$23.5M vs +$5.7M prior year
- Adjusted gross margin q3
- 70.7% vs 72.1% prior year (pro forma)
- Limb reconstruction growth
- +8.5% reported / +9.4% constant currency
- Therapeutic solutions growth
- +4.5%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.